BEIJING, April 1 (Xinhua) — In the late 1980s, Michael Kinch was a young scientist bent on solving the biggest medical problem of his time: developing an AIDS vaccine. At that time, dozens of well-funded laboratories are tackling this problem, AIDS vaccine seems to be out of call, Jinqi also participated in.
New coronavirus vaccine developed by Chinese Academy of Military Sciences
More than 30 years have passed, the world’s AIDS-dying people more than 30 million people, but no AIDS vaccine has been approved for sale. According to Jinqi, the development process for the AIDS vaccine is undoubtedly alarming for those who expect to be able to use the new coronary pneumonia vaccine next year.
“People assume that a new coronary pneumonia vaccine will be developed, and we need to deal with this issue calmly, ” he said. “
With the number of confirmed cases in the world exceeding 850,000, governments, investors and the public in countries and regions around the world are closely watching the progress of the development of the new coronary pneumonia vaccine in the hope that the vaccine will prevent further spread of the outbreak. Researchers are seen as a saviour, and U.S. President Donald Trump has even called on major pharmaceutical companies to “get it done.”
In the eyes of the vast majority of the public, vaccines are simple: let the immune system “see” key parts of a virus or virus and remember them so that they can be easily dealt with when they are actually infected. Vaccines are much cheaper than drugs and provide decades of or lifetime immunity.
However, developing a vaccine is no easy task. Most vaccines usually take years to test before they go on sale, and it’s too fast to develop a vaccine in 12 to 18 months. The fastest-developing new coronary pneumonia vaccine uses new technologies, which have not yet been proven to be effective against humanvaccines.
Even vaccines developed using mature technology can have side effects and the scope of use can be limited or even out of service at all. For example, a vaccine for Lyme disease, an infectious disease that develops symptoms such as measles and fever from tick bites, developed by Smith Kline Beecham, was removed from the shelves in 2002 because of the potential for arthritis.
Even the most prestigious experts can turn the clock in predicting when the vaccine will come out. In 1984, Margaret Heckler, the U.S. secretary of health and human services, said that an AIDS vaccine would enter the trial phase within two years. Unfortunately, researchers have never achieved this goal.
Typically, vaccine sdevelopment takes up to 10 years or more, and this time vaccine experts have adopted new technologies that speed up the development process. Anthony Fauci, director of the National Institute of Infectious Diseases, and other experts predict that the new coronary pneumonia vaccine could go on sale in the next 12-18 months. Dozens of companies and universities around the world have joined the vaccine development competition, including Sanofi, Johnson and Johnson and Moderna.
Moderna uses a more advanced technique to add viral genetic material to human cells to induce cells to produce proteins that produce an immune response. Moderna said on March 16 that it had treated the first case of new coronary pneumonia in early research.
Holden Thorp, editor-in-chief of the Journal of Science, points out that the new technology has not been proven and that no one can guarantee the success of a messenger RNA vaccine or similar vaccine. Failure to achieve the desired success will not only harm society, but also undermine public trust in science.
It takes 2 times as long.
Worryingly, says Mr Thorpe, “there is a lot of expectation that people can achieve a certain goal ahead of time, and if they don’t, they’re going to die.” In the long run, I fear that the public will think that science cannot solve the problems it faces, which will do long-term harm to science.”
There are similar problems with drugs for new coronary pneumonia, and the results of a clinical trial of Reddit, which Gilead originally developed to treat Ebola, will be released in April. Regeneron Pharmaceuticals said earlier in March that the process of developing a new coronary pneumonia drug was faster than expected and would enter human trials this summer.
U.S. volunteers receive new crown vaccinations
Vaccine companies need to double the amount of time they need to achieve their goals. The Alliance for Innovation in Epidemiological Prevention funds at least eight vaccines. Melanie Saville, head of vaccine research, says they have built multiple production platforms that can be put into production as soon as a vaccine is successful. Even if a vaccine can be developed within the desired time frame, she says, there is a high probability that it will not be approved in time and can only be used in an emergency.
In terms of safety, Mr Ginch says, the standard of vaccine must be higher than medicines because it is for healthy people whose goal is to stop themselves from contracting a disease. Companies may demand exemptionfrom responsibility for safety issues caused by the new coronapneumonia vaccine, and government departments under intense pressure may compromise.
The company that developed the new coronary pneumonia vaccine has attracted investor interest, with Moderna’s share price up about 50 per cent so far this year and Inovio Pharmaceuticals, which uses DNA-based technology to develop vaccines, more than doubling. Inovio Pharmaceuticals plans to launch human trials in the United States in April. China’s Concino Bio said in March that it had received regulatory approval to conduct similar tests.
“People are overly optimistic about vaccines,” says Dmitry Kuzmin, managing partner at venture capital firm 4BIO Capital. “
But There are also some positive signs in vaccine development, Kuzmin said. Pharmaceutical companies are advancing different technologies, including traditional methods, increasing the probability of successful vaccine development.
Unlike HIV, The new coronavirus appears to mutate at a relatively low rate, meaning the vaccine can be used for a period of time, Jinqi said. One of the big problems, he says, is that once most people are infected before the vaccine goes on the market, the vaccine is basically useless, “I’m 100 percent sure of the vaccine, but the reality is that we’re in a race against the virus, we’re 4-5 behind, and we have to catch up.”
‘In the long run, vaccines and drugs will be available, but interventions could kill the new coronary pneumonia outbreak,’ said Andrew Ward, a professor at the Scripp Institute and a virus expert. Governments in countries and regions around the world have taken a variety of measures, including a ban on the spread of the epidemic.
“New crown pneumonia is a public health emergency, and it may be public health measures, not science, that will beat it,” he said. “